We hypothesized that Ezh2, by modulating H3K27 methylation, may directly regulate monocyte to M2-like immunomodulatory macrophage differentiation and thus represents an attractive therapeutic target to design new pharmacological epigenetic inhibitors to promote cardiac repair post-MI and prevent the occurrence of heart failure. Here, EZH2 is linked to myocardial infarction.